ECSP15035530A - Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas - Google Patents
Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricasInfo
- Publication number
- ECSP15035530A ECSP15035530A ECIEPI201535530A ECPI201535530A ECSP15035530A EC SP15035530 A ECSP15035530 A EC SP15035530A EC IEPI201535530 A ECIEPI201535530 A EC IEPI201535530A EC PI201535530 A ECPI201535530 A EC PI201535530A EC SP15035530 A ECSP15035530 A EC SP15035530A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- tetrayclic
- heterociclo
- treatment
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a nuevos Compuestos Tetracíclicos Sustituidos con Heterociclo de Fórmula (I); y sales farmacéuticamente aceptables de los mismos, en la que A, A', R2, R3, R4 y R5 son como se han definido en el presente documento. La presente invención también se refiere a composiciones que comprenden al menos un Compuesto Tetracíclico Sustituido con Heterociclo, y métodos de uso de los Compuestos Tetracíclicos Sustituidos con Heterociclo para tratar o prevenir la infección por el VHC en un paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/000038 WO2014110687A1 (en) | 2013-01-16 | 2013-01-16 | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP15035530A true ECSP15035530A (es) | 2017-08-31 |
Family
ID=51208906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201535530A ECSP15035530A (es) | 2013-01-16 | 2015-08-17 | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
Country Status (26)
Country | Link |
---|---|
US (1) | US9555038B2 (es) |
EP (1) | EP2945952B1 (es) |
JP (3) | JP6093451B2 (es) |
KR (1) | KR101748974B1 (es) |
CN (1) | CN105073755B (es) |
AP (1) | AP2015008625A0 (es) |
AR (1) | AR094496A1 (es) |
AU (1) | AU2013374112B2 (es) |
BR (1) | BR112015016325A2 (es) |
CA (1) | CA2898049C (es) |
CL (1) | CL2015001971A1 (es) |
CR (1) | CR20150378A (es) |
DO (1) | DOP2015000169A (es) |
EA (1) | EA030554B1 (es) |
EC (1) | ECSP15035530A (es) |
HK (1) | HK1211290A1 (es) |
IL (1) | IL239832A0 (es) |
MA (1) | MA38315B1 (es) |
MD (1) | MD20150075A2 (es) |
MX (1) | MX356203B (es) |
PE (1) | PE20151892A1 (es) |
PH (1) | PH12015501560A1 (es) |
SG (1) | SG11201505536RA (es) |
TN (1) | TN2015000293A1 (es) |
TW (1) | TW201441231A (es) |
WO (2) | WO2014110687A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014110687A1 (en) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
US10457690B2 (en) | 2015-06-04 | 2019-10-29 | Merck Sharp & Dohme Corp. | Process for preparing substituted tetracyclic heterocycle compounds |
US20180228826A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US20180228828A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US20190002480A1 (en) * | 2015-12-21 | 2019-01-03 | Merck Sharp & Dohme Corp. | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases |
WO2017181383A1 (en) | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
WO2017219808A1 (zh) * | 2016-06-21 | 2017-12-28 | 浙江柏拉阿图医药科技有限公司 | 丙型肝炎病毒抑制剂及应用 |
WO2018032468A1 (en) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
WO2018032467A1 (en) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases |
CN109206396B (zh) * | 2017-07-05 | 2023-03-28 | 上海迪赛诺化学制药有限公司 | 2-c-甲基-4,5-o-(1-甲基乙烯基)-d-***糖酸乙酯的制备方法 |
CN109232612A (zh) * | 2017-07-11 | 2019-01-18 | 周龙兴 | 抑制丙肝病毒的化合物、药物组合物及其用途 |
US20210361663A1 (en) * | 2018-10-26 | 2021-11-25 | Merck Sharp & Dohme Corp. | Formulations of Antiviral Compounds |
TW202317145A (zh) * | 2021-06-17 | 2023-05-01 | 美商亞堤製藥公司 | 有利之抗hcv組合療法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
AU2001293817A1 (en) | 2000-09-20 | 2002-04-02 | Merck Patent Gmbh | 4-amino-quinazolines |
CA2531511A1 (en) | 2003-07-10 | 2005-01-20 | Paradigm Therapeutics Ltd. | Silicon compounds and their use |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
JP4143669B2 (ja) | 2004-02-24 | 2008-09-03 | 日本たばこ産業株式会社 | 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
EP1807397A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
US7994360B2 (en) | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
US20110104109A1 (en) | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
CN101213190A (zh) | 2005-07-14 | 2008-07-02 | Irm责任有限公司 | 用作tpo模拟物的化合物和组合物 |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
FR2894963A1 (fr) | 2005-12-16 | 2007-06-22 | Inst Nat Sante Rech Med | Nouveaux composes interagissant avec pea-15 |
US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7642251B2 (en) | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US20110130361A1 (en) | 2007-08-09 | 2011-06-02 | Jonathan Grimm | Silicon derivatives as histone deacetylase inhibitors |
EP2187883A2 (en) | 2007-08-10 | 2010-05-26 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2715839C (en) | 2008-02-13 | 2014-12-09 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
CN102159285B (zh) | 2008-07-22 | 2014-05-14 | 默沙东公司 | 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物 |
WO2010041687A1 (ja) | 2008-10-09 | 2010-04-15 | コニカミノルタホールディングス株式会社 | 有機光電変換素子、太陽電池及び光センサアレイ |
WO2010062821A1 (en) | 2008-11-28 | 2010-06-03 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
EP2411038B1 (en) | 2009-03-27 | 2016-12-28 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
SG10201402969QA (en) * | 2009-03-27 | 2014-09-26 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 c형 간염 억제제 |
AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
ES2558554T3 (es) | 2010-03-09 | 2016-02-05 | Merck Sharp & Dohme Corp. | Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
WO2012040923A1 (en) * | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
CA2811752A1 (en) * | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases |
WO2012041014A1 (en) * | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives for treating hepatitis c virus infection |
WO2014110688A1 (en) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases |
WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
-
2013
- 2013-01-16 WO PCT/CN2013/000038 patent/WO2014110687A1/en active Application Filing
- 2013-12-31 MD MDA20150075A patent/MD20150075A2/ro not_active Application Discontinuation
- 2013-12-31 MX MX2015009225A patent/MX356203B/es active IP Right Grant
- 2013-12-31 EA EA201591328A patent/EA030554B1/ru not_active IP Right Cessation
- 2013-12-31 PE PE2015001352A patent/PE20151892A1/es not_active Application Discontinuation
- 2013-12-31 AP AP2015008625A patent/AP2015008625A0/xx unknown
- 2013-12-31 SG SG11201505536RA patent/SG11201505536RA/en unknown
- 2013-12-31 WO PCT/CN2013/001676 patent/WO2014110705A1/en active Application Filing
- 2013-12-31 BR BR112015016325A patent/BR112015016325A2/pt not_active Application Discontinuation
- 2013-12-31 MA MA38315A patent/MA38315B1/fr unknown
- 2013-12-31 CA CA2898049A patent/CA2898049C/en not_active Expired - Fee Related
- 2013-12-31 KR KR1020157021818A patent/KR101748974B1/ko active IP Right Grant
- 2013-12-31 CN CN201380074735.2A patent/CN105073755B/zh not_active Expired - Fee Related
- 2013-12-31 JP JP2015551946A patent/JP6093451B2/ja not_active Expired - Fee Related
- 2013-12-31 US US14/761,256 patent/US9555038B2/en active Active
- 2013-12-31 EP EP13871363.1A patent/EP2945952B1/en active Active
- 2013-12-31 AU AU2013374112A patent/AU2013374112B2/en not_active Ceased
-
2014
- 2014-01-16 TW TW103101674A patent/TW201441231A/zh unknown
- 2014-01-16 AR ARP140100153A patent/AR094496A1/es unknown
-
2015
- 2015-06-29 TN TNP2015000293A patent/TN2015000293A1/fr unknown
- 2015-07-08 IL IL239832A patent/IL239832A0/en unknown
- 2015-07-13 PH PH12015501560A patent/PH12015501560A1/en unknown
- 2015-07-13 CL CL2015001971A patent/CL2015001971A1/es unknown
- 2015-07-16 CR CR20150378A patent/CR20150378A/es unknown
- 2015-07-16 DO DO2015000169A patent/DOP2015000169A/es unknown
- 2015-08-17 EC ECIEPI201535530A patent/ECSP15035530A/es unknown
- 2015-12-08 HK HK15112117.6A patent/HK1211290A1/xx unknown
-
2016
- 2016-11-07 JP JP2016217169A patent/JP6148779B2/ja not_active Expired - Fee Related
- 2016-11-18 JP JP2016225137A patent/JP6417380B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP15035530A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
CO6592102A2 (es) | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
DOP2013000238A (es) | Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
CL2018002528A1 (es) | Agentes anti virales de la hepatitis b. | |
CR20160337A (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b | |
UY37997A (es) | Agentes antivirales contra la hepatitis b | |
UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
CR20150085A (es) | Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b | |
CR20160140A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
CR20110059A (es) | Compuestos organicos | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
DOP2019000140A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
BR112017003242A2 (pt) | composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto. | |
DOP2014000034A (es) | Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
UY32875A (es) | Derivados de benzodiazepinas para tratar infección de hepatitis c. | |
BR112014015582A2 (pt) | compostos antivirais | |
BR112015000392A2 (pt) | novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório |